iRhythm Narrows Losses, Boosts Revenue by 31% on Strong Zio System Adoption

Ticker: IRTC · Form: 10-Q · Filed: Oct 30, 2025 · CIK: 1388658

Sentiment: bullish

Topics: Medical Devices, Digital Health, Cardiac Monitoring, Earnings Report, Revenue Growth, Loss Reduction, Healthcare Technology

Related Tickers: IRTC, PHG, MDT

TL;DR

**IRTC is finally turning the corner with massive loss reduction and strong revenue growth, making it a buy for long-term growth.**

AI Summary

iRhythm Technologies, Inc. (IRTC) reported significant revenue growth and a reduced net loss for the three and nine months ended September 30, 2025. Revenue for the three months ended September 30, 2025, increased by 30.7% to $192.88 million from $147.54 million in the prior year period. For the nine months ended September 30, 2025, revenue grew 25.9% to $538.25 million, up from $427.51 million in the same period of 2024. The net loss for the third quarter of 2025 dramatically improved to $5.21 million, a 88.7% reduction from a net loss of $46.18 million in Q3 2024. The nine-month net loss also decreased by 55.2% to $50.13 million from $111.96 million in the prior year. Operating expenses saw a slight decrease in Q3 2025 to $145.55 million from $151.78 million in Q3 2024, primarily due to a significant reduction in acquired in-process research and development expenses from $32.07 million to $0.30 million. Cash and cash equivalents decreased to $255.61 million as of September 30, 2025, from $419.60 million at December 31, 2024, largely due to substantial purchases of marketable securities totaling $340.54 million.

Why It Matters

This filing indicates iRhythm is making strides towards profitability, which is crucial for investor confidence in a competitive medical device market. The substantial reduction in net loss and robust revenue growth suggest increasing adoption of its Zio System, potentially strengthening its market position against rivals like Philips and Medtronic in ambulatory cardiac monitoring. For employees, this signals a more stable and growing company, while customers benefit from continued innovation in cardiac diagnostic services. The broader market could see this as a positive indicator for the digital health sector, especially in remote patient monitoring, driving further investment and innovation.

Risk Assessment

Risk Level: medium — While net loss significantly decreased, the company still reported a net loss of $5.21 million for the quarter and $50.13 million for the nine months ended September 30, 2025. Additionally, cash and cash equivalents declined by $163.99 million during the nine-month period, indicating continued cash burn despite improved operational performance.

Analyst Insight

Investors should consider initiating or increasing positions in IRTC, given the strong revenue growth of 30.7% and the dramatic 88.7% reduction in net loss. Monitor future filings for continued progress towards sustained profitability and positive cash flow from operations, as the company is still operating at a net loss.

Financial Highlights

debt To Equity
N/A
revenue
$192.88M
operating Margin
-4.37%
total Assets
$995.21M
total Debt
$648.75M
net Income
-$5.21M
eps
N/A
gross Margin
71.14%
cash Position
$255.61M
revenue Growth
+30.7%

Revenue Breakdown

SegmentRevenueGrowth
Product and Service Revenue$192.88M+30.7%

Key Numbers

Key Players & Entities

FAQ

What were iRhythm Technologies' key financial results for Q3 2025?

iRhythm Technologies reported revenue of $192.88 million for the three months ended September 30, 2025, a 30.7% increase from $147.54 million in Q3 2024. The net loss significantly decreased by 88.7% to $5.21 million, compared to a net loss of $46.18 million in the prior year period.

How did iRhythm Technologies' operating expenses change in Q3 2025?

Total operating expenses for iRhythm Technologies decreased slightly to $145.55 million in Q3 2025 from $151.78 million in Q3 2024. This reduction was primarily driven by a substantial decrease in acquired in-process research and development expenses, which fell from $32.07 million in Q3 2024 to $0.30 million in Q3 2025.

What is the Zio System and its significance for iRhythm Technologies?

The Zio System is iRhythm Technologies' proprietary system combining an FDA-cleared, wire-free, patch-based biosensor with cloud-based data analytic software. It provides ambulatory cardiac monitoring services like LTCM and MCT, allowing clinicians to diagnose arrhythmias more efficiently, and is central to the company's revenue generation.

What was iRhythm Technologies' cash position at the end of Q3 2025?

As of September 30, 2025, iRhythm Technologies had cash and cash equivalents of $255.61 million. This represents a decrease from $419.60 million at December 31, 2024, largely due to $340.54 million in purchases of marketable securities during the nine-month period.

What are the primary risks highlighted in iRhythm Technologies' 10-Q filing?

The filing highlights risks related to global business, political, and macroeconomic conditions, including inflation, interest rate volatility, and supply chain disruptions. It also mentions risks concerning government and third-party payor coverage and reimbursement, and the ability to obtain and maintain intellectual property protection.

How has iRhythm Technologies' net loss per common share changed?

For the three months ended September 30, 2025, iRhythm Technologies' net loss per common share was $(0.16), a significant improvement from $(1.48) in Q3 2024. For the nine months ended September 30, 2025, the net loss per common share was $(1.57), down from $(3.59) in the prior year period.

What strategic outlook does iRhythm Technologies have for its products?

iRhythm Technologies plans to modify its current systems and services, and identify or acquire new products to address additional indications. The company also expects continued growth of its business and organization, including expansion of its sales and marketing efforts in international geographies.

What was the change in iRhythm Technologies' total assets from year-end 2024 to Q3 2025?

iRhythm Technologies' total assets increased to $995.21 million as of September 30, 2025, from $931.45 million at December 31, 2024. This increase was primarily driven by a rise in marketable securities from $115.96 million to $309.61 million and property and equipment, net, from $125.09 million to $149.32 million.

What is iRhythm Technologies' current market capitalization based on outstanding shares?

As of October 23, 2025, iRhythm Technologies had 32,219,143 shares of common stock outstanding. To determine the market capitalization, this number would need to be multiplied by the current stock price, which is not provided in the filing.

Where are iRhythm Technologies' main operational facilities located?

iRhythm Technologies is headquartered in San Francisco, California, which also serves as a clinical center. Additional clinical centers are located in Deerfield, Illinois, and Houston, Texas, with a manufacturing facility in Cypress, California, and corporate office space in Solana Beach, California.

Risk Factors

Industry Context

iRhythm operates in the rapidly evolving remote cardiac monitoring market, a segment driven by technological advancements in wearable sensors and AI-driven diagnostics. The industry is characterized by increasing demand for non-invasive, continuous monitoring solutions to improve patient outcomes and reduce healthcare costs. Key trends include the shift towards integrated care platforms and the growing adoption of telehealth services.

Regulatory Implications

As a medical device company, iRhythm is subject to rigorous regulatory oversight by the FDA and international bodies. Compliance with evolving regulations, including those related to data privacy (e.g., HIPAA) and device cybersecurity, is critical. Any failure to maintain compliance or any adverse regulatory actions could significantly impact market access and financial performance.

What Investors Should Do

  1. Monitor SG&A expenses closely.
  2. Evaluate the strategic allocation of cash.
  3. Assess the sustainability of R&D investment.
  4. Track progress towards profitability.

Key Dates

Glossary

Acquired in-process research and development
Costs associated with research and development projects acquired from another company that have not yet reached technological feasibility and have no alternative future use. (A significant reduction in these expenses from $32.07 million in Q3 2024 to $0.30 million in Q3 2025 was a primary driver for the improved net loss.)
Marketable securities
Short-term, highly liquid investments that can be readily converted into cash. (The company significantly increased its investment in marketable securities by $224.65 million (from $115.96M to $309.61M) during the nine months ended September 30, 2025, impacting its cash position.)
Accumulated deficit
The total cumulative net losses of a company since its inception, less any cumulative net income. (iRhythm's accumulated deficit stood at $809.03 million as of September 30, 2025, reflecting its history of net losses, though the rate of increase has slowed.)
Deferred revenue
Revenue that has been received by a company but not yet earned, typically from advance payments for goods or services to be delivered in the future. (Deferred revenue increased from $2.93 million to $4.22 million, suggesting an increase in future service commitments.)
Operating lease right-of-use assets
An asset representing the right to use a leased asset over the lease term, recognized under ASC 842. (These assets decreased from $47.56 million to $43.30 million, indicating a reduction in the company's leased space or equipment.)

Year-Over-Year Comparison

Compared to the prior year period, iRhythm Technologies has demonstrated robust revenue growth, with Q3 2025 revenue increasing by 30.7% to $192.88 million. This top-line expansion has been accompanied by a significant improvement in profitability, as the net loss narrowed by 88.7% to $5.21 million in Q3 2025, largely due to a substantial decrease in acquired in-process R&D expenses. Total assets have grown to $995.21 million from $931.45 million, while cash and cash equivalents have decreased due to strategic investments in marketable securities.

Filing Stats: 4,539 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2025-10-30 17:21:56

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 1

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited): 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Comprehensive Loss 3 Condensed Consolidated Statements of Cash Flows 4 Condensed Consolidated Statements of Stockholders' Equity 6 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 29

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 40

Controls and Procedures

Item 4. Controls and Procedures 41

OTHER INFORMATION

PART II. OTHER INFORMATION 42

Legal Proceedings

Item 1. Legal Proceedings 42

Risk Factors

Item 1A. Risk Factors 43

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 81

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 81

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 81

Other Information

Item 5. Other Information 82

Exhibits

Item 6. Exhibits 82 Exhibit Index 82

Signatures

Signatures 83 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements concerning our plans, objectives, and expectations for our business, operations, and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would", and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: the expected impact of global business, political, and macroeconomic conditions, including inflation, interest rate volatility, cybersecurity events, potential instability in the global banking system, volatile market conditions, the impact of tariffs, the impact of any significant political and regulatory developments, global events, including public health crises, and ongoing geopolitical conflicts, such as the war in Ukraine and conflict in the Middle East, on our business, operations, and financial results; the impact of supply chain disruptions on our operations and financial results; the impact of inflationary costs on our operations and financial results; plans to conduct further clinical studies, including any clinical trials initiated by third parties; our plans to modify our current systems and services,

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS IRHYTHM TECHNOLOGIES, INC. Condensed Consolidated Balance Sheets (In thousands, except par value) September 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 255,605 $ 419,597 Marketable securities 309,608 115,956 Accounts receivable, net 76,157 79,941 Inventory 19,559 14,039 Prepaid expenses and other current assets 19,106 16,286 Total current assets 680,035 645,819 Property and equipment, net 149,316 125,092 Operating lease right-of-use assets 43,300 47,564 Restricted cash 8,358 8,358 Goodwill 862 862 Long-term strategic investments 68,091 61,902 Other assets 45,252 41,852 Total assets $ 995,214 $ 931,449 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 8,278 $ 7,221 Accrued liabilities 117,882 84,900 Deferred revenue 4,224 2,932 Operating lease liabilities, current portion 16,526 15,867 Total current liabilities 146,910 110,920 Long-term senior convertible notes 648,753 646,443 Other noncurrent liabilities 9,926 8,579 Operating lease liabilities, noncurrent portion 67,732 74,599 Total liabilities 873,321 840,541 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock, $ 0.001 par value – 5,000 shares authorized; none issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value – 100,000 shares authorized; 32,434 shares issued and 32,205 shares outstanding at September 30, 2025, respectively; and 31,621 shares issued and 31,392 shares outstanding at December 31, 2024, respectively 32 31 Additional paid-in capital 955,601 874,607 Accumulated other comprehensive income 285 165 Accumulated deficit ( 809,025 ) ( 758,895 ) Treasury stock, at cost; 229 shares at September 30, 2025 and December 31, 2024 ( 25,000 ) ( 25,000 ) Total stockholders' equity 121,893 90,908 Total liabilities and stockholders' equity $ 995,214 $ 931,449 The accompanying notes are an integra

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing